{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T13:07:20Z","timestamp":1749215240548,"version":"3.28.2"},"reference-count":31,"publisher":"Informa UK Limited","issue":"8","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1080\/13543784.2021.1948010","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T03:42:51Z","timestamp":1624506171000},"page":"797-801","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Still grasping at straws: donanemab in Alzheimer\u2019s disease"],"prefix":"10.1080","volume":"30","author":[{"given":"Sheila A","family":"Doggrell","sequence":"first","affiliation":[{"name":"Doggrell Biomedical Communications, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,7,8]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_3_3_3_1","DOI":"10.1056\/NEJMoa2100708"},{"unstructured":"Alzheimer\u2019s facts and figures [cited 2021 April 14] Available from: https:\/\/www.alz.org\/alzheimers-dementia\/facts-figures","key":"e_1_3_3_4_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_5_1","DOI":"10.1016\/j.cell.2019.09.001"},{"doi-asserted-by":"publisher","key":"e_1_3_3_6_1","DOI":"10.1186\/s13195-021-00809-4"},{"doi-asserted-by":"publisher","key":"e_1_3_3_7_1","DOI":"10.1186\/s13195-018-0424-5"},{"doi-asserted-by":"publisher","key":"e_1_3_3_8_1","DOI":"10.1016\/j.neuron.2012.10.029"},{"doi-asserted-by":"publisher","key":"e_1_3_3_9_1","DOI":"10.1016\/j.jalz.2018.06.2378"},{"key":"e_1_3_3_10_1","doi-asserted-by":"crossref","first-page":"e12112","DOI":"10.1002\/trc2.12112","article-title":"Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease","volume":"7","author":"Lowe SL","year":"2021","unstructured":"Lowe SL, Willis BA, Hawdon A, et al. Donanemab (LY3002813) dose-escalation study in Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 2021;7:e12112.","journal-title":"Alzheimer\u2019s Dement"},{"doi-asserted-by":"publisher","key":"e_1_3_3_11_1","DOI":"10.1038\/s41582-018-0116-6"},{"doi-asserted-by":"publisher","key":"e_1_3_3_12_1","DOI":"10.1159\/000340056"},{"doi-asserted-by":"publisher","key":"e_1_3_3_13_1","DOI":"10.3233\/JAD-200808"},{"doi-asserted-by":"publisher","key":"e_1_3_3_14_1","DOI":"10.1016\/j.arr.2019.100948"},{"unstructured":"ClinicalTrials.gov. A follow-on study of donanemab (LY3002813) with video assessments in participants with Alzheimer\u2019s disease (TRAILBLAZER-EXT). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04640077?term=DONANEMAB&draw=2&rank=2 [cited 2021 April 23]","key":"e_1_3_3_15_1"},{"unstructured":"ClinicalTrials.gov. A study of donanemab (LY3002813) in participants with early Alzheimer\u2019s disease (TRAILBLAZER-ALZ 2). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04437511?term=DONANEMAB&draw=2&rank=1#studydesc [cited 2021 April 23]","key":"e_1_3_3_16_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_17_1","DOI":"10.1080\/14728214.2020.1808621"},{"doi-asserted-by":"publisher","key":"e_1_3_3_18_1","DOI":"10.1056\/NEJMoa1705971"},{"unstructured":"ClinicalTrials.gov. Clinical trial of solanezumab for older individuals who may be at risk of memory loss (A4). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02008357?term=solanezumab&draw=2&rank=5. [cited 2021 April 26]","key":"e_1_3_3_19_1"},{"unstructured":"ClinicalTrials.gov. A study of gantenerumab in participants with prodromal Alzheimer\u2019s disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01224106?term=nct01224106&draw=2&rank=1. [cited 2021 June 14]","key":"e_1_3_3_20_1"},{"unstructured":"ClinicalTrials.gov. A study of gantenerumab in participants with mild Alzheimer Disease. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02051608?term=nct02051608&draw=2&rank=1. [cited 2021 June 14]","key":"e_1_3_3_21_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_22_1","DOI":"10.1186\/s13195-019-0559-z"},{"doi-asserted-by":"publisher","key":"e_1_3_3_23_1","DOI":"10.1186\/s13195-021-00813-8"},{"unstructured":"ClinicalTrials.gov. A study to confirm safety and efficacy of lecanemab in participants with early Alzheimer\u2019s disease (Clarity AD). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03887455?term=lecanemab&draw=2&rank=2. [cited 2021 April 26]","key":"e_1_3_3_24_1"},{"unstructured":"ClinicalTrials.gov. AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer\u2019s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer\u2019s Disease and Intermediate Amyloid. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04468659?term=lecanemab&draw=2&rank=1. [cited 2021 April 26]","key":"e_1_3_3_25_1"},{"unstructured":"221AD301 Phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (ENGAGE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02477800?term=ADUCANUMAB&draw=2&rank=7 [cited 2021 June 6]","key":"e_1_3_3_26_1"},{"unstructured":"221AD302 Phase 3 study of aducanumab (BIIB037) in early Alzheimer\u2019s disease (EMERGE) https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02484547?term=ADUCANUMAB&draw=2&rank=6 [cited 2021 June 6]","key":"e_1_3_3_27_1"},{"unstructured":"EMERGE and ENGAGE topline results . Two phase 3 studies to evaluate aducanumab in patients with early Alzheimer\u2019s disease. https:\/\/investors.biogen.com\/static-files\/8e58afa4-ba37-4250-9a78-2ecfb63b1dcb [cited 2021 June 6]","key":"e_1_3_3_28_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_29_1","DOI":"10.1186\/s13195-021-00838-z"},{"doi-asserted-by":"publisher","key":"e_1_3_3_30_1","DOI":"10.1002\/alz.12213"},{"doi-asserted-by":"publisher","key":"e_1_3_3_31_1","DOI":"10.1001\/jama.2021.3854"},{"unstructured":"FDA grants accelerated approval for Alzheimer\u2019s drug. [cited 2021 June 6]. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-grants-accelerated-approval-alzheimers-drug","key":"e_1_3_3_32_1"},{"doi-asserted-by":"publisher","key":"e_1_3_3_33_1","DOI":"10.1080\/14712598.2018.1543397"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1948010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T08:46:04Z","timestamp":1732610764000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1948010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["10.1080\/13543784.2021.1948010"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1948010","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"type":"print","value":"1354-3784"},{"type":"electronic","value":"1744-7658"}],"subject":[],"published":{"date-parts":[[2021,7,8]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-05-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-06-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-08","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}